Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Press releases
Our latest press releases
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results
Regulatory press release
11/11/2026
Hansa Biopharma to participate in Jefferies Global Healthcare Conference in London
10/11/2026
Hansa Biopharma presenting at Stifel 2026 Healthcare Conference
05/11/2026
Hansa Biopharma to participate in BIO-Europe 2026
04/11/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
